 |
> 1994 Publications
1. GNRH
agonists for the treatment of advanced prostate cancer: managed
care implications.
Trotter J, Greenstein F, Hom R, McLeod DG, Moul JW, Reich P, and
Smith B:
Med. Interface 7(7) supplement; 14-32, 1994. |
2. People
gaining bowel and bladder control. In: Guidelines and Recommendations
for Two Models of Continence Care.
Moul, JW:
Multidisciplinary Incontinence Clinic Task Force, The Pelvic Health
Center: Spartanburg, SC:
HIP, Inc, 9-24, 1994. |
3. Oncogenes
and tumor suppressor genes. Moul JW, Gaddipati J and Srivastava
S. Molecular biology of prostate cancer.
Current Clinical Oncology: Prostate Cancer.
(Eds. Dawson, N.A. and Vogelzang, N.J.),
Wiley-Liss Publications, 19-46, 1994. |
4. Treatment-Post-prostatectomy
incontinence. In: Clinicians Desk Reference: Assessment, Treatment,
and Management of Incontinence.
Moul JW: Spartanburg, SC:
HIP, Inc. 1994. |
5. Prostatic
cancer and BPH.
Moul JW:
Postgrad. Med. 96(1): 24-25, (letter) 1994. |
6. For
incontinence after prostatectomy, tap a diversity of treatments.
Moul JW:
Contemp. Urol., 6(4):78-88, 1994. |
7. DNA
ploidy in nonseminomatous germ cell testicular tumor.
Moul JW:
Urology, 44:151-152, (letter), 1994. |
8.
AUA Yesterday: James Claude Kimbrough: The Father of
Modern U.S. Army Urology.
Moul JW:
Part I: AUA Today 6(12):8-10, 1993;
Part II: AUA Today 7(1):9-12, 1994. |
9. An
important goal of prostatectomy: Minimizing incontinence.
Moul JW:
Contemp. Urol., 6(3): 15-28, 1994. |
10. Testicular
cancer in blacks: a multicenter experience.
Moul JW, Schanne FJ, Thompson IM, Frazier HA, Peretsman SA, Wettlaufer
JN, Rozanski TA, Stack RS, Kreder KJ, and Hoffman KJ:
Cancer 73:388-93, 1994. |
11.
Percentage of embryonal carcinoma and vascular invasion predict
pathologic stage in clinical stage I nonseminomatous testicular
cancer.
Moul JW, McCarthy WF, Fernandez EB, and Sesterhenn IA:
Cancer Research. 54:362-64, 1994 |
12. Immunocytological
detection of prostate cancer pelvic lymph node micrometastases:
correlation to preoperative serum prostate specific antigen.
Moul JW, Lewis DJ, Ross AA, Kahn DG, Ho CK, and McLeod DG:
Urology 43:68-73, 1994. |
13.
Thymic hyperplasia in newly diagnosed testicular germ
cell tumor patients.
Moul JW, Fernandez EB, Bryan MG, Stuart P, Ho CK, and McLeod
DG:.
J Urol 152:1480-1483, 1994. |
14. Evaluation
of Cathepsin-D and epidermal growth factor receptor in prostate
carcinoma.
Maygarden SJ, Novotny DB, Moul JW, Bae VL, and Ware JL:
Mod. Pathol. 7:930-936, 1994. |
15. Immunohistochemical
expression of p53 tumor suppressor gene protein in adult germ
cell testis tumors: clinical correlation in stage I disease.
Lewis DJ, Sesterhenn IA, McCarthy WF, Moul JW:
J Urol, 152:418-423, 1994. |
16. Perirenal
liposarcoma containing extramedullary hematopoiesis associated
with renal cell carcinoma.
Lewis DJ, Moul JW, Williams SC, Colon E, and Sesterhenn IA:
Urology 43:106-09, 1994. |
17. Analysis
of the tumor suppressor gene p53 in xeroderma pigmentosam fibroblasts.
Lavu S. Srivastava M, and Srivastava S.
Cancer Letter, 85: 9-12, 1994. |
18.
Inhibition of the retinoblastoma (RB) protein phosphorylation
by combined effect of gamma-interferon and tumor necrosis factor-alpha.
Janat FM, Srivastava S, Devadas K, Chin GA, Pirollo KF and Chang
E.
Mol. and Cell. Differentiation, 241-253, 1994. |
19. Clinically
detected carcinoma of the prostate treated by radical prostatectomy
in a 29 year old man.
Heidenberg HB, Moul JW, Mostofi FK and McLeod DG:
J Urol, 152:966-967, 1994. |
20. Frequent
detection of codon 877 mutation in the androgen receptor gene
in advanced prostate cancers.
Gaddipati J, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ,
Moul JW and Srivastava S.
Cancer Research, 54:2861-2864, 1994. |
 Back
to Top |  Next
Page |
|
